Showing results (511-520 of 601) with videos related to
Sort By:
Pageof 61
American Journal of Hematology|April 5, 2013
Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patientsAli T Taher, John B Porter, Vip Viprakasit, et al.Bioorganic & Medicinal Chemistry|August 11, 2010
Modulation of the inhibitor properties of dipeptidyl (acyloxy)methyl ketones toward the CaaX proteasesAnne-Marie R Dechert, James P MacNamara, Sarah R Breevoort, et al.Blood Cells, Molecules & Diseases|February 9, 2016
Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS studyAli T Taher, M Domenica Cappellini, Yesim Aydinok, et al.Journal of Medicinal Chemistry|July 21, 1998
Selective endothelin A receptor antagonists. 3. Discovery and structure-activity relationships of a series of 4-phenoxybutanoic acid derivativesP C Astles, C Brealey, T J Brown, et al.Journal of Medicinal Chemistry|July 21, 1998
Selective endothelin A receptor antagonists. 4. Discovery and structure-activity relationships of stilbene acid and alcohol derivativesP C Astles, T J Brown, F Halley, et al.The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|August 19, 1999
An analysis of the effect of age on survival after heart transplantA M Borkon, G F Muehlebach, P G Jones, et al.Blood|January 4, 2014
A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA)Dudley J Pennell, John B Porter, Antonio Piga, et al.Blood Advances|February 8, 2024
Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiencyEduard J van Beers, Hanny Al-Samkari, Rachael F Grace, et al.Transfusion|June 3, 2008
Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusionsEllen B Fung, Paul R Harmatz, Meredith Milet, et al.British Journal of Haematology|October 27, 2025
Achieving clinically meaningful changes in haemoglobin levels in patients with non-transfusion-dependent β-thalassaemia treated with luspatercept: A post hoc analysis of the phase 2 BEYOND trialKhaled M Musallam, Ali T Taher, John B Porter, et al.Pageof 61